BPC-157
BPC-157: FDA status after the July 2026 advisory vote, how thin the human evidence is, sport bans and sourcing risks.
Not FDA-approved · Evidence grade D · Reviewed
BPC-157 (Body protection compound). Synthetic peptide.
DNot FDA-approved. Evidence grade D: animal and lab data only.
What is BPC-157?
BPC-157 is a synthetic peptide promoted for injury recovery and gut health.
Is BPC-157 FDA-approved?
Not approved for any use. FDA flagged it for safety concerns in 2023. In July 2026 an FDA advisory committee narrowly recommended adding it to the list of substances pharmacies may compound. The vote is advisory. It is not FDA approval, and nothing changes legally until FDA finishes rulemaking. The use the committee considered was ulcerative colitis. FDA staff had advised that it did not meet the standard for listing.
What does the evidence show for BPC-157?
Almost entirely animal and laboratory studies. Published human data cover only a few dozen people.
What are the known risks of BPC-157?
Long-term safety in people is unknown. It is banned in sport at all times under the World Anti-Doping Code.
How is BPC-157 measured?
Products sold online as "research use only" have no assurance of identity, dose or sterility. The calculator can do the arithmetic for any vial, but it cannot tell you what is actually in one.
Sources: AJMC: FDA panel backs 6 peptides for compounding; Pharmacy Times: what the peptide vote changes; Black Health: what the FDA peptide vote changed. This profile does not recommend any dose or use.
For research and educational use. Not medical advice. Regulatory status changes, so confirm the current position with FDA or a licensed professional.